COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Protocol No
ECOG-EA5182
Principal Investigator
Jonathan Thompson
Phase
III
Summary
This study is being done to answer the following question: By adding an additional drug to the drug that is typically given, can we increase the time the cancer is controlled by the treatment? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your non-small cell metastatic EGFR-mutant lung cancer. The usual approach is defined as care most people get for metastatic EGFR-mutant lung cancer.
Description
Testing the addition of bevacizumab to AZD9291 (osimertinib) as a first-treatment for patients with EGFR-mutant lung cancer that has metastasized
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category